ClinicalTrials.gg
CompletedNCT00998075Updated Dec 7, 2010

Study Comparing Esomeprazole and Acetylsalicylic Acid (ASA) Combined Together as One Capsule Versus These Medications Taken Separately

A Phase 1 interventional study of Esomeprazole/ASA Fixed Combination and Esomeprazole - Nexium in Peptic Ulcer Disease, sponsored by AstraZeneca. Completed at 1 site in Canada. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-12-07.

Sponsored by AstraZeneca · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to investigate whether treatment with a combination capsule of Esomeprazole 40 mg and Aspirin (ASA) 325 mg is bioequivalent (i.e.has the same effect within the body) as these medications taken separately. Two different forms of esomeprazole (tablets and capsules) will be investigated.

02

Conditions studied

  • Peptic Ulcer Disease

Browse trials for

Keywords

  • Bioequivalence
  • ASA
  • Esomeprazole
  • peptic ulcer disease
  • primary cardiovascular protection
  • healthy volunteers
03

In context

Peptic Ulcer

146 studies on the registry are indexed under Peptic Ulcer; 25 are open to participants now.

This study's enrollment of 138 is below the median of 165 across 105 interventional studies indexed under Peptic Ulcer.

Browse Peptic Ulcer studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smoking male or female within the age range of 20 to 50 years
  • (BMI = weight/height2) greater than or equal to 18.5 kg/m2 and less than or equal to 29.9 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Documented upper gastrointestinal surgery
  • Use of any proton pump inhibitors or any bismuth preparations (e.g. Pepto-Bismol®) within 14 days preceding the screening visit
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
138 participants (actual)

Study arms

  • Active comparator
    1

    Esomeprazole 40 mg/ASA 325 mg Fixed Dose Combination Capsule

    Drug: Esomeprazole/ASA Fixed Combination

  • Active comparator
    2

    Esomeprazole Clinical Trial Capsule 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg

    Drug: Esomeprazole - Nexium · Drug: ASA

  • Active comparator
    3

    Esomeprazole MUPS Tablet 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg

    Drug: Esomeprazole - Nexium · Drug: ASA

Interventions

  • DrugEsomeprazole/ASA Fixed Combination

    Capsule, oral, single dose

  • Clinical Trial Capsule or MUPS Tablet, oral, single dose

  • DrugASA

    Tablet, oral, single dose

    Also known as: Aspirin

06

What researchers measure

Primary outcomes

  1. Plasma concentration-time curve from time 0 to the last quantifiable concentration for esomeprazole administered as fixed dose combination (FDC) to esomeprazole administered as free combinations

    Time frame: PK samples to be taken for bioanalysis over a 24-hour period following dosing on Day 1 of Period I and Day 1 of Period II and III.

Secondary outcomes

  1. Pharmacokinetics (PK): Total area under the plasma concentration-time curve (AUC0-inf), AUC0-t, Cmax, time to Cmax (Tmax), and half-life (t½) of esomeprazole

    Time frame: PK samples to be taken for bioanalysis over a 24-hour period following dosing for each treatment arm

07

Study locations

1 site
  • Research Site
    Scarborough, Ontario, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2009
First posted
Oct 20, 2009
Start
Sep 2009
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Last update
Dec 7, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00998075
Lead sponsor
AstraZeneca
First posted
Oct 20, 2009
Start date
Sep 2009
Primary completion
Dec 2009
Completion
Dec 2009
Last update
Dec 7, 2010

Study contacts

TJørgen Næsdal, MD, PhD
study director · AstraZeneca R&D
Pierre Geoffroy, M.D. C.M., M.S
principal investigator · Biovail Contract Research (BCR)a Division of Biovail Corporation
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Esomeprazole · Aspirin

Start the discussion